vTv Therapeutics (NASDAQ:VTVT) Announces Earnings Results, Beats Expectations By $0.32 EPS

vTv Therapeutics (NASDAQ:VTVT) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.32, Zacks reports.

vTv Therapeutics Price Performance

Shares of VTVT traded down $0.66 during mid-day trading on Thursday, reaching $17.60. The stock had a trading volume of 66,179 shares, compared to its average volume of 23,309. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $30.99. The firm has a market cap of $56.14 million, a price-to-earnings ratio of -3.89 and a beta of 1.07. The business’s fifty day moving average is $16.85 and its 200 day moving average is $15.42.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VTVT. StockNews.com initiated coverage on shares of vTv Therapeutics in a research note on Wednesday. They issued a “sell” rating on the stock. Alliance Global Partners initiated coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.